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Abstract.
Background: Transmissible spongiform encephalopathies (TSEs) are rare neurodegenerative disorders that affect animals
and humans. Bovine spongiform encephalopathy (BSE) in cattle, and Creutzfeld-Jakob Disease (CJD) in humans belong
to this group. The causative agent of TSEs is called “prion”, which corresponds to a pathological form (PrPSc) of a normal
cellular protein (PrPC) expressed in nerve cells. PrPSc is resistant to degradation and can induce abnormal folding of PrPC,
and TSEs are characterized by extensive spongiosis and gliosis and the presence of PrPSc amyloid plaques. CJD presents
initially with clinical symptoms similar to Alzheimer’s disease (AD). In AD, tau aggregates and amyloid- protein plaques
are associated with memory loss and cognitive impairment in patients.
Objective: In this work, we study the role of tau and its relationship with PrPSc plaques in CJD.
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Methods: Multiple immunostainings with specific antibodies were carried out and analyzed by confocal microscopy.
Results: We found increased expression of the glial fibrillary acidic protein (GFAP) and matrix metalloproteinase (MMP-9),
and an exacerbated apoptosis in the granular layer in cases with prion disease. In these cases, tau protein phosphorylated at
Thr-231 was overexpressed in the axons and dendrites of Purkinje cells and the extensions of parallel fibers in the cerebellum.
Conclusion: We conclude that phosphorylation of tau may be a response to a toxic and inflammatory environment generated
by the pathological form of prion.
Keywords: Cerebellum, neuronal death, prion encephalopathy, prion protein, tau protein
INTRODUCTION
Transmissible spongiform encephalopathies
(TSEs) form a group of rare and incurable neu-
rodegenerative diseases. Although TSEs have long
incubation episodes, disease progression is inex-
orable and rapid. The initial clinical manifestations
are heterogeneous, with disturbances in memory,
gait coordination, personality, and behavior [1–3].
Once the clinical symptoms appear [1], patients die
within 6–9 months for sporadic cases, and up to 10
years for genetic cases [4, 5]. The etiologic agent
for TSE is termed “prion” (the word being derived
from “proteinaceous infectious particle”), according
to the nature and ability of an altered protein species
(scrapie-associated prion protein, PrPSc) to induce
a change in the conformational structure of PrPC
(cellular prion protein,) [6, 7]. Physiological roles for
PrPC includes copper homeostasis, protection against
stress, cell adhesion, and neuronal excitability [6, 8].
PrPSc can cause TSEs and is extremely resistant to
thermal decontamination and sterilization methods
that are effective against viruses, bacteria, and fungi
[9]. Once PrPSc has entered the central nervous
system (CNS), progressive neurological signs and
degenerative morphological changes (spongiosis,
gliosis, and PrPSc-amyloid plaques) appear [1],
invariably culminating in rapid death [1, 10]. Human
TSEs can be grouped into three classes: I) genetic
cases associated with mutations in the gene encoding
PrPC, including Familial Creutzfeld-Jakob Disease
(fCJD), Gertsmann-Straussler-Scheinker Syndrome
(GSS), and Fatal Familial Insomnia (FFI) [5]; II)
sporadic cases of CJD (sCJD) and FFI (sFFI) [11];
and III) cases caused by the accidental transmission
of a pathogenic prion by surgical procedures such
as iatrogenic CJD (iCJD) or “new variant” CJD
(nvCJD) caused by oral ingestion of bovine spongi-
form encephalopathy (BSE) [4]. Approximately 350
new CJD cases (1 per million people) are reported
annually in the United States, comprising 1% iatro-
genic, 14% genetic, and 85% sporadic forms [12].
Although cerebellar dysfunction is the prominent
symptom of TSEs [1, 11], clinical signs indicate
that the brainstem, middle brain, hypothalamus, hip-
pocampus, and cerebral cortex may also be affected
[2, 3, 5, 11]. Pre-mortem diagnosis consists of
encephalograms (EEG), magnetic resonance imag-
ing (MRI), and positron emission tomography (PET)
[5]. However, a definitive diagnosis is only confirmed
postmortem through immunohistochemical evidence
of PrPSc lesions [1, 5].
In contrast, neurodegenerative disorders termed
“tauopathies” are a group of sporadic or famil-
ial neurodegenerative diseases characterized by the
accumulation of fibrillar and hyperphosphorylated
tau in neurons and glial cells [13]. Extracellular
plaques composed of an amyloid- (A) core sur-
rounded by dystrophic neurites [14] are observed in
AD, the most common tauopathy in which patholog-
ical tau protein and A plaques are associated with
cognitive dysfunction [15].
Differential diagnosis between the early stages of
prion disease and AD is not well established as very
similar symptoms appear in both conditions, with the
primary difference being that dementia occurs rapidly
in prion disease [16, 17]. In this study, we analyzed
the expression of PrPSc and tau in the cerebellar tissue
of prion disease, AD, and healthy patients. In prion
disease, PrPSc deposits aggregate and accumulate as
prion plaques. Astrogliosis favors an aggravated brain
inflammation and neuronal death of the cerebellar
granular layer (GL). The presence of hyperphospho-
rylated tau has been reported in cases of human TSEs
[16–20]. Here, we observed the presence of tau phos-
phorylated at Thr-231 in the axons and dendrites of
Purkinje cells and in parallel fibres of the surviv-
ing granular cells. This suggests that phosphorylation
may be increased by the exacerbated inflammatory
activity caused by astrogliosis in prion diseases.
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Table 1
Characterisation of cases
Sex Age at Presenting symptoms Disease Diagnosis
death (y) duration (mo)
Male 57 Mental disorders and rapid progression of gait disorders 15 sCJD
Female 65 Progressive ataxia for gait 8 sCJD
Male 76 Dementia syndrome of rapid evolution with gait apraxia 15 sCJD
Female 33 Alterations in gait and progressive dementia 10 sCJD
Female 55 Throbbing headache followed by episodes of sudden forgetfulness 26 fCJD
Female 43 Rapidly evolving memory loss 12 fCJD
Female 47 Sensory neuropathy and cerebellar syndrome 72 GSS
Male 47 Dementia severe AD
Female 80 Dementia severe AD
Male 80 Dementia severe AD
Male 47 Pneumonia CONTROL
Male 79 Pneumonia CONTROL
Female 57 Pneumonia CONTROL
sCJD, sporadic Creutzfeld-Jakob disease; fCJD, familial Creutzfeld-Jakob disease; GSS, Gertsmann-Straussler-Scheinker syndrome; AD,
Alzheimer’s disease; CONTROL, brains without neurodegenerative disease.
MATERIALS AND METHODS
Brain tissue
This study examined the brain tissue of seven
patients diagnosed with prion disease (Table 1).
All cerebellar sections included representative cell
areas of the molecular layer (ML), Purkinje and
granular cells, and white matter (Wm). The tissues
were obtained from the National Dementia BioBank,
FESC, UNAM, according to the institutional guide-
lines of bioethics. The cerebellum of patients with
prion disease, AD, and those without neurodegen-
erative disease was maintained in a 10% formalin
solution. The fragments were submerged in 10%
sucrose in PBS for 24 h and subsequently cut into
50-m thick coronal slices on a sliding microphone
(Leica, Heidelberg. Germany).
Immunohistochemistry
Free-floating tissue sections were pretreated with
H2O2 (0.3% in PBS), to block endogenous perox-
idase activity, for 10 min. Non-specific antibody
binding sites were blocked with an IgG free albu-
min solution (0.2% in PBS). Tissues were incubated
with the primary antibody cocktail (Table 2) diluted
in 0.2% Triton X-100 in PBS (Sigma-Aldrich
Co.) overnight at 4◦C. Immunoreactivity was visu-
alized using horseradish peroxidase (HRP) and
3-3-diaminobenzidine (DAB, Sigma-Aldrich Co.)
as chromogen. Sections were counterstained with
hematoxylin.
Table 2
List of primary antibodies used for immunohistochemistry and
immunofluorescence studies
Antibody Protein / Epitope Source
3F4 PrPC and PrPSc : aa109–112 BioLegend
pTau231 Tau: Phospho-Thr231 Invitrogen
pTau396 Tau: Phospho-Ser396 Invitrogen
pTau416 Tau: Phospho-Ser416 Abcam
CP13 Tau: Phospho-Ser202 [21]
TG3 Tau: Regional conformational
change with phosphorylation at
Thr231 and Ser235
[22]
PHF-1 Tau: Phospho–396/404 Invitrogen
Tau-C3 Tau: Truncation at Asp421 [23]
423 Tau: Truncation at Glu391 [24]
NF-L Neurofilament - light Abcam
GFAP Reactive astroglia (glial
fibrillary acidic protein)
GeneTex
MMP-9 Active matrix metalloprotease 9 Invitrogen
ssDNA F7-26 Fragmented DNA Chemicon
Immunofluorescence
Antigenic epitopes were retrieved using a cit-
rate buffer (0.1 M citric acid, 0.1 M sodium citrate,
pH 6.0) at 100◦C for 30 min. Lipofuscin autofluo-
rescence was removed with Sudan B Black (SBB)
solution (SPI® Supplies, West Chester, PA) (0.1%
SBB in 70% ethanol) for 10 min. Non-specific sites
were blocked with IgG-free albumin solution (0.2%
Sigma-Aldrich Co.) in PBS at room temperature for
20 min. Tissues were then incubated with the pri-
mary antibody cocktail (Table 2) diluted in 0.2%
Triton X-100 (Sigma-Aldrich Co.) in PBS overnight
at 4◦C. Primary antibodies were revealed with the
appropriate secondary antibody coupled to different
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Fig. 1. Immunofluorescent staining of the prion protein. a) Low magnification where a folia of the cerebellum is observed, in which there is
strong 3F4 immunoreactivity. The nuclei are stained blue with TO-PRO(R)-3. b) Amplification of classic prion plaques that are characterized
by a dense core (DC) and, in the periphery, diffuse staining in the shape of a crown (arrows) is observed, whereas in other structures (short
arrows) a dense core is not observed.
fluorochromes: Dylight®-488 (Vector Laboratories,
CA, USA) and rhodamine isothiocyanate-TRITC
(Jackson ImmunoResearch Laboratories, Inc., West
Grove, PA, USA). Sections were counterstained with
TO-PRO®-3 (Thermo Fisher Scientific) and mounted
on slides with anti-photobleaching medium Vec-
tashield (Vector Laboratories).
Confocal microscopy
Double and triple-immunolabeled sections were
examined using a confocal laser scanning microscope
(TCS-SP8, Leica, Heidelberg, Germany) using the
20x, 40x, and 100x lenses. Ten to fifteen consec-
utive individual sections were sequentially scanned
at 0.8–1.0 m intervals for two or three channels
throughout the z-axis of the sample. The collected
images were projected and analyzed onto the two-
dimensional plane using a pseudocolor display of
green (FITC, excitation spectrum: 488 nm), red
(TRITC, excitation spectrum: 540 nm), and blue (TO-
PRO®-3, spectrum excitation: 650 nm).
RESULTS
Presence of prion plaques in human cerebellum
Prion encephalopathies are fatal progressive neu-
rodegenerative diseases. These diseases affect both
animals and humans. In humans, only 10% of cases
are of genetic etiology; the rest are of either spo-
radic or infectious origin. The clinical diagnosis of
these diseases is based on accelerated and short-
term cognitive impairment. Histopathologically, the
nervous tissue has cavities and prion amyloido-
genic plaques throughout the brain parenchyma.
Plaques are revealed using specific markers, such
as the anti-prion 3F4 antibody. Thus, a confirma-
tory diagnosis was performed by staining against
this prion protein in cerebellar slices. There were a
large number of 3F4-immunoreactive plaques in the
cerebellum (Fig. 1a) for all prion disease cases ana-
lyzed. In Fig. 1a, a cerebellar folia with many prion
plaques (green channel, arrows), counterstained with
TO-PRO(R)-3 to show nuclei, is shown at low magni-
fication. Prion plaques were characterized by a dense
core (DC), highly immunoreactive to the 3F4 anti-
body, surrounded by a fuzzy crown (Fig. 1b, arrows).
The DC was made up of several small spheres joined
together. Diffuse plaques were also present (Fig. 1b,
short arrows).
PrPC distribution
In the cerebellum, PrPC expression pattern in the
Wm (Fig. 2a, arrows) and in the ML (Fig. 1c, arrows)
suggest that PrPSc aggregates, expressed probably in
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Fig. 2. Location of PrPC and PrPSc in the cerebellum. 3F4 reactivity shows the cytoplasmic localization of PrPC in Wm (a), in GL (b), and
ML (c). Cells with PrPC cytoplasmic expression appear to correspond in shape, size, and location to astrocytes. PrPSc aggregates increase
in size and density of Wm (d), GL (e), and ML (f). GL, Granular layer; ML, Molecular layer; Wm, white matter; P, Purkinje cells. Images
obtained using a Leica SP8 confocal microscope.
the fibrous astrocytes of the Wm and protoplasmic
of the neuropil of the GL and ML, originated from
PrPC. 3F4 immunoreactivity was located in the cell
cytoplasm in both GL and ML (Fig. 2b, c, arrows). No
prion plaques were observed in the Wm (Fig. 2a). The
structures observed corresponded to small lump-like
cell aggregates and residual cell granules of approx-
imately 5–10 m in length (Fig. 2d, e), suggesting
that they may be the minimal nuclei that eventually
form the prion plaques in the ML (Fig. 2f).
Aggregation of PrPSc in the cerebellum
The pattern of PrPSc aggregates observed in Fig. 2
(d-f) was observed in all of the prion disease cases.
Figure 3 corresponds to the stages of prion particle
aggregation, suggesting that prion plaque forma-
tion begins with aggregation of cellular components.
These structures are packed in a membrane (Fig. 3a).
Diffuse staining around the plaques suggests that free
PrPSc induces the replication and conversion of PrPC
into PrPSc (Fig. 3b). The accumulation of packed cel-
lular structures gives rise to dense aggregates (Fig. 3c,
d), which increase in size until generating the insol-
uble plaques observed in the ML of the cerebellum
(Fig. 3e, f).
Mechanism of cell death in prion infection
The expression of reactive astrocytes, matrix
metalloproteinase-9 (MMP-9), and apoptotic bodies
were analyzed to determine the type of neuronal death
and those cells affected in prion disease. Reactive
astrocytes were distinguished in the ML (Fig. 4a,
arrows), GL (Fig. 4b, c), and Wm (Fig. 4d, arrows).
Although astrogliosis was evident in all layers of
the cerebellum, GFAP staining was most robust in
GL. This implied damage, cellular hypertrophy, and
destruction of nearby neurons in this region (Fig. 4b,
c, arrows).
In contrast, it has been reported that MMP-9 is
highly expressed in the brains of AD patients, asso-
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Fig. 3. PrPSc deposits in the different cerebellar layers. Immunofluorescence was performed with the anti-PrP 3F4 monoclonal antibody.
Small arrows show prominent PrPSc plaques and long arrows show cell aggregates. a) Aggregates of 5–10 m in diameter are observed in
the Wm. b) PrPSc aggregates become denser and seem to attract others towards the GL (c). d, e) Dense aggregates interact with others, giving
rise to prion plaques with a size larger than 50 m (f). GL: granular layer. ML, molecular layer; Wm, white matter. Images obtained using a
Leica SP8 confocal microscope.
ciated with a neuroprotective role in response to
neuronal death caused by A plaques [25, 26]. The
ML (outermost layer) contains the parallel fibers that
run through the cortical layer of the cerebellum, the
dendritic projections of the Purkinje cells, interneu-
rons (superficial stellate cells and deep basket cells)
that establish GABAergic synapses on Purkinje neu-
rons, and neuroglia. The GL is composed of granular
cells, Golgi type II cells, cerebellar glomeruli, and
protoplasmic astrocytes. In ML, MMP-9 expression
was located in structures that morphologically corre-
spond to glial structures (Fig. 5a). MMP-9 was not
evident in the Purkinje cell layer (Fig. 5b). MMP-9
immunoreactivity was more marked in GL than in
ML (Fig. 5b, c). Finally, abundant MMP-9 was also
observed in the Wm, suggesting that astrocytes are
expressing this protein in response to PrPSc aggrega-
tion, similar to what occurs with plaques (Fig. 5d).
To demonstrate the phenomenon of apoptosis in
the cerebellum, the ssDNA antibody F7–26 was used.
Apoptotic cells were distributed in the cerebellar cor-
tex, mainly in the GL (Fig. 6a, b), with much less
reactivity towards the ML (Fig. 6a, b). The Wm is the
region with intrinsic fibers that connect the cerebellar
hemispheres; the afferents of the spinal cord and the
cerebral cortex and the efferents consisting mainly of
the axons of Purkinje cells). In Wm, apoptotic bodies
were not observed (Fig. 6c). These structures were
associated with an increased GFAP-positive astro-
cytic activity (Fig. 4), indicating that the type of cells
that die in prion infection was granular (Fig. 6d).
Purkinje cells and other cells located in the ML
were not affected. The distribution of small PrPSc-
aggregates (Fig. 2d, e, f, and Fig. 3) and the expression
of MMP-9 (Fig. 5) in the Wm and the neuropil of the
cerebellar cortex suggest that the conversion of the
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Fig. 4. Astrogliosis in the layers of the cerebellum in prion disease. GFAP immunohistochemistry revealed a highly variable expression
pattern in the different cell layers. Between ML a) and GL (b, c), a dramatic increase in reactive astrocytes (arrows) was observed. d) In the
Wm, astrocytosis is kept in a smaller quantity. ML, Molecular layer; GL, Granular layer; Wm, white matter. White arrows point out Purkinje
neurons.
PrPC in PrPSc, and the loss of protective function of
astrocytes in the recapture of neurotransmitters, gen-
erate a toxic environment that induces the granular
cell death. Cell death triggers the expression of tau
phosphorylated at Thr-231, avoiding the collapse of
the neuronal circuit of the afferent fibers (correspond-
ing to the mossy fibers (coming from the nuclei of
the bridge and the spinal cord), climbing (somatosen-
sory cortex and the lower olive), serotonergic (Rafe
nuclei) and noradrenergic (locus coeruleus) systems),
axons of the Purkinje cells and the deep nuclei
projections. The collapse of this cytoarchitecture
could be due to the cytotoxic environment produced
more by oxidative glutamate toxicity than by PrPSc
plaques.
Tau phosphorylation in prion disease
PrPSc plaques were abundant in the ML (Figs. 1
and 2). 3F4-reactive plaques appeared to have a uni-
form distribution both on the outermost (Fig. 7a) and
innermost foliae, closest to the deep nuclei (Fig. 7b).
The size and number of PrPSc plaques were also
significant, demonstrating that PrPC could interact
with PrPSc in the ML. Cell integrity could be noted
in the parallel fibers (Fig. 7c) with the pTau231
antibody. Axonal torpedoes, formed in response
to cerebellar lesions, increased in number accord-
ing to the state of atrophy of the cerebellum [27].
There was no immunoreactivity with the pTau396
antibody, which reacts with tau phosphorylated at
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Fig. 5. MMP-9 expression in the different layers of the cerebellum. From the outermost layer to the Wm, in a) abundant MMP-9 expression
(arrows) is observed in the ML, decreasing the expression towards the Purkinje cell layer in b), in c) MMP-9 increases considerably in the
GL. In d) MMP-9 is observed in the Wm. The dotted lines show the point of intersection between one neural layer and another. P, Purkinje
cells; ML, Molecular layer; GL, Granular layer; Wm, White matter. Images obtained using a Leica SP8 confocal microscope.
Ser396 (Fig. 7d). The other tau antibodies used
in this study against tau post-translational changes
(pTau416, CP13, TG3, PHF1, TauC3, 423) did not
show any immunoreactivity in the cerebellum (data
not shown). The absence of colocalization between
the PrP plaques and pTau231 indicated that there
was no direct interaction between these structures
(Fig. 7a). Axons and dendrites of the Purkinje cells
were intact, thus the neurotoxic response produced
by the prion plaques near the parallel fibers (which
regulate the cells in the basket, the stellate cells,
and the Purkinje cells) did not interrupt their excita-
tory activity. Plaques increased tau phosphorylation
at Thr-231. Phosphorylation at this site may act
as a neuroprotective signal in response to the neu-
rotoxic environment (produced by prion plaques,
located in the ML, converting PrPC to PrPSc (Figs. 2
and 3), and the collapse of neuronal cytoarchitec-
ture due to the granular cell death (Fig. 7a). To
identify a possible neuroprotective role for tau, we
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Fig. 6. Staining of apoptotic cells in the cerebellum. a, b) Marked immunostaining of cell apoptosis (green) in the cerebellar folia. c) There
is no reactivity in the Wm. d) The nuclei of the intact granular cells (blue) and the damaged ones (green) in the GL are shown at 100X
magnification. P, Purkinje cells; ML, Molecular layer; GL, Granular layer; Wm, White matter. Images obtained using a Leica SP8 confocal
microscope.
analyzed different cases according to disease dura-
tion with the levels of expression of pTau231. Tau
expression was similar for eCJD, fCJD, and GSS
patients (Fig.7a, c). In cases of eCJD (Fig. 7a), fCJD
(Fig. 7b), and GSS (Fig. 7c), the extent of tau phos-
phorylation at pTau231 was similar. The levels of
expression of tau phosphorylated at Thr-231 pro-
duced by the neurotoxic environment, plaques, and
free PrPSc were increased in TSEs. Tau phospho-
rylation at Thr-231 is a neuroprotective response
to neurodegeneration caused by the collapse of the
neuronal cytoarchitecture, loss of function of astro-
cytes, and massive granular cell death. It supports
the idea that tau aggregates do not contribute to the
clinico-pathological characteristics in the terminal
stages of prion diseases. To demonstrate this, we
analyzed and compared the expression of neurofil-
aments between prion disease, AD (Fig. 8b), and
healthy cases (Fig. 8c). Tau phosphorylation at Thr-
231 and overexpression of neurofilaments modulated
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Fig. 7. Phosphorylated tau in the cerebellum. In a) and b) pT231 reactivity (red) demonstrates phosphorylation of tau at Thr-231 in both
external and internal folia, respectively. Aggregated PrPSc (green) and nuclei (blue) are shown. c) Parallel fibers stained with pT231 in
the ML. d) No reactivity is observed with the pT396 antibody. In the magnification of b), axons of the Purkinje cells recognized with the
pT231 antibody are indicated. ML, molecular layer; Wm, white matter; P, Purkinje cells. Images obtained using a Leica SP8 confocal
microscope.
the axonal cytoskeleton in response to the prion
(merged image, Fig. 8a).
DISCUSSION
The intricate pattern of tau phosphorylation and its
relationship to the prion aggregation is still unknown.
Even the mechanism that initiates the conversion of
PrPC to PrPSc remains poorly understood. It has been
suggested that alteration of PrPC to PrPSc may take
place in the endoplasmic reticulum, where proteins
appear defective after synthesis and are translocated
to the cytosol for degradation in the proteasome via
the endoplasmic-reticulum-associated protein degra-
dation (ERAD) pathway [28, 29]. Our observations in
Fig. 2a, b, and c are consistent with this mechanism.
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Fig. 8. The pTau231 immunoreactivity pattern is similar in the cerebellum of familial and sporadic TSEs. a) Absence of interaction between
PrPSc and pTau. A positive reaction to pTau231 (red) in the axons of the Purkinje cells, and the projections of the parallel fibers from the
granular cells is observed, (b) F33-10 (eECJ), (c) F55-26 (fECJ), and (d) F47–72 (GSS). The identifier for cases corresponds to the sex, age
(yrs), and duration of the disease (months). P, Purkinje cell.
PrPC in the cytoplasm undergoes the conformational
change to PrPSc (Fig. 2d-f) which accumulates as
aggregates in the cerebellum (Fig. 1d, e). These
aggregates, which vary in size, appear to be the ini-
tiators of the aggregation events that ultimately form
the extracellular prion protein plaques observed in
the ML (Fig. 1f and Fig. 2d-f). Prion plaques would
not be the cause of the replication of the agent, but
rather the free PrPSc, which is seen as diffuse staining
around the aggregates (Fig. 3a-d). The PrPSc is likely
to arise from astrocytes, interneurons, and granular
cells since the 3F4 immunoreactivity is localized in
regions where these cells are most abundant. Previ-
ous studies have shown that PrP knockout astrocytes
influence the neuronal survival in the regulation of
glutamatergic neurotransmission [30]. Both astro-
cytes and microglia are harmful in CJD [31–34].
According to our observations we suggest that, in
astrocytes, the glutamatergic transmission is made
via the synapses of mossy fibers (in GL) and granular
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Fig. 9. Presence of neurofilaments in cases of prion disease. a) In prion diseases, the expression of Nf-L is increased and co-localizes with
the tau phosphorylated at Thr-231. b, c) In AD and healthy brains, the expression of neurofilaments is similar, whereas the pTau231 antibody
does not exhibit any signal. Sections were contrasted with TO-PRO(R)-3 as a background control. CJD, Creutzfeld-Jakob disease; AD,
Alzheimer’s disease; ND, Non-dementia. Images obtained using a Leica SP8 confocal microscope.
cells with their lateral fibers on Purkinje neurons (in
ML) (Fig. 10). Phosphorylation of tau decreases MT
binding, and is observed during neurodegeneration
in AD [35–38]. This post-translational modification
has been reported in sporadic, familial, and acquired
forms of prion diseases. Paired helical filaments
appear in rare genetic prion diseases, such as neo-
cortical areas in GSS [29] and thalamus in FFI [18].
Neurofibrillary tangles have been found in the frontal
cortex, cerebellum, and hippocampus in familial and
sporadic CJD [17, 19]. In TSE, dystrophic neurites
associated with prion plaques were observed; these
prion plaques were negative for A antibodies and
positive for PrPSc [39]. Tau-laden dystrophic neu-
rites are commonly associated with A plaques in
AD [40]. Hyperphosphorylated tau protein has also
been detected in neurons and glial cells of transgenic
mice infected with BSE [41]. Previous studies have
documented that PrPSc induces tubulin oligomeriza-
tion and that the presence of the tau protein could
be capable of protecting the microtubule from the
effect of the PrP protein [42]. Furthermore, the accu-
mulation and replication of PrPSc disrupts biological
processes, distinctly in different cell types [43]. In our
study, prion plaques have a heterogeneous pattern of
aggregation and localization depending on the type of
TSE [39], the polymorphism involved, and duration
of the disease [11].
Phosphorylation of tau at Thr231 in the axons
and dendrites of the Purkinje cells, and parallel
fibers from granule cells, is a response to neuronal
loss in the GL and prion aggregates (Figs. 7 and
8). These observations suggest that phosphorylation
at Thr231 could prevent microtubule depolymeriza-
tion and regulate the neurotoxic effect of the prion
protein. Neurofilaments provide the structural sup-
port for myelinated axons, essential for effective
nerve conduction, organelles and synaptic vesicles
dynamic [44]. Figures 7 and 8 showed that pTau231
overexpression is linked to its neuroprotective role
against prion plaques (and represented schematically
in Fig. 10). This suggests that PrPSc deposits do
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Fig. 10. Dynamics of cerebellar dysfunction in TSEs. (Left) Astrocytes regulate the glutamatergic transmission of granular cells (blue) in
healthy cerebellum. (Right) PrPSc causes protoplasmic astrocyte dysfunction (pink) and reactive astrocyte activation (orange). It increases
the cytotoxic Glu concentration, causes neuronal death, the CG (gray) of the cerebellar glomeruli, and activates the phosphorylation of tau
to prevent the depolymerization of the parallel fibers that innervate the Purkinje cells (red). ML, molecular layer; GL, granular layer; Wm,
white matter. Question marks represent pathways that have not yet been demonstrated in the literature.
not induce the neurofibrillary changes observed in
the cerebellum. The integrity of Purkinje cells may
indicate that early tau phosphorylation may prevent
breakdown of the microtubule network and the loss
of the cerebellar neuronal circuit.
Taking into account the differences in PrPSc plaque
aggregation (Fig. 3) and the role of astrocytes in the
neuroinflammatory response, what is the role of PrPSc
in the loss and death of granule cells in the cere-
bellum? Considering that reactive astrocytes respond
to pathological brain situations, such as ischemia,
infection, and neurodegenerative diseases [31], we
hypothesize that the loss in function of astrocytes con-
tributes to neurodegeneration in TSEs. In this work,
a detailed examination was performed to confirm
the role of astrocytes in the granular cell apoptosis.
The temporal and anatomical correlation between the
PrPSc deposition, reactive astrogliosis located mainly
in GL (Fig. 4), and neuropathological damage evi-
denced by MMP-9 (Fig. 5), suggest that PrPSc has
an increased tendency to aggregate from the cellular
debris observed in the Wm (Fig. 2d). Astrogliosis
has been shown as a hallmark of prion diseases,
being induced by PrPSc [7, 21, 32, 33, 45, 46].
MMP-9, expressed in response to stimuli such as pro-
inflammatory peptides and cytokines caused by the
prion particle [26, 47, 48] and activated microglia,
are present both in sporadic and genetic TSEs, and
animal models infected with prions [49]. Microglia
release interleukin IL1- in response to neurotoxic-
ity caused by PrPSc aggregates, similar to that which
occurs in AD with A plaques [13] and, in turn, pro-
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Fig. 11. Hypothetical scheme of the neurotoxic environment produced by the proliferation of reactive astrocytes and its relationship with the
loss of function of PrPC in the cerebellum. Astrocytes can be stimulated by signaling cascades that result in detrimental effects on the neural
environment. Hyperexcitability of NMDA receptors and loss of function of AMPA receptors to maintain the balance of Zn2+ and Cu2+ ions
can lead to increased oxidative stress and cell death. The conformational change from PrPC to PrPSc initiates the aggregation of the insoluble
plaques, producing a neuroinflammatory response of the microglia, releasing pro-inflammatory cytokines that activate astrogliosis. Both the
death of granule cells and the toxic environment produced by prion plaques could initiate the phosphorylation of tau to maintain innervation
on Purkinje cells. EAAT, Excitatory amino acid transporter. Question marks represent pathways that have not yet been demonstrated in
the literature. NOS: nitric-oxide synthase; AMPAR: AMPA receptor; ROS: reactive oxygen species; ECM: extracellular matrix; MMP-9:
matrix metalloproteinase-9, IL-1B: interleukin 1 beta; Glu: glutamate, PSD: postsynaptic density protein; NMDAR: N-methyl-D-aspartate
receptor; JNK: c-Jun N-terminal kinase; ERK: extracellular signal-regulated kinase; PKC: protein kinase C.
motes the secretion of MMP-9 by reactive astrocytes
[26, 47]. On the other hand, PrPC is known to mod-
ulate NMDA-type glutamate receptors by mediating
plasticity and synaptic transmission [8], and acting as
a divalent ion sensor, regulating the balance of Cu2+
and Zn2+ via AMPA receptors [50, 51]. We hypoth-
esize that astrogliosis increases the concentration of
extracellular glutamate, leading to hyperexcitability
of NMDA receptors. This causes increased intracel-
lular Ca2+ and NOS and the release of Cyt-C via
calpain [52], leading to apoptosis due to oxidative
stress. AMPA receptors may be related to superoxide
dismutase (SOD) dysfunction, due to (a) decrease in
the concentration of enzymatic cofactors (Cu2+ and
Zn2+); (b) loss of PrPC function (by its conversion to
PrPSc); and (c) its proteolysis by the activity of MMP-
9 (Fig. 11). The distribution of reactive astrocytes
was observed in parallel with the PrPSc topography.
DNA fragmentation, however, was exclusive to the
GL (Fig. 6) suggesting that the damage is produced
by free radicals due to astrocytic activity and excess
extracellular glutamate [30]. Previous immunocyto-
chemical and expression studies of Bax, Bcl-2, Fas,
and Casp-3, have shown inconsistencies, since only
Bax and not Casp-3 expression was reported [53, 54].
Furthermore, the anti-apoptotic activity of Bcl-2 was
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reported to reduce neuronal loss in the cerebellum of
transgenic mice [55]. A toxic PrP form could be pro-
duced directly from PrPC expressed in cells of the GL,
discarding a direct neurotoxic role for PrPSc plaques.
Our findings support apoptosis as the relevant cell
death pathway in TSEs. However, this pathway may
be activated, in turn, by a further pathway.
CONCLUSION
Our study suggests that an early event that prevents
MT destabilization in prion disease is the phospho-
rylation of tau at Thr-231. Reactive astrocytes and
the loss of homeostasis in the interstitium lead to
death of granular cells and the development of prion
pathology. This reactive astrocytosis would be a key
event in the pathological mechanisms related to prion
disease (as depicted in Fig. 11). Consequent tissue
damage could arise via the following pathways: 1)
intracellular accumulation of PrPc forms affects cel-
lular function and leads to neuronal death; free PrPSc
observed around the dense plaques acts as the cyto-
toxic factor as opposed to the extracellular deposits
of PrPSc within plaques; 2) tau protein responds to
the presence of prion plaques; and 3) astrogliosis and
elevated MMP-9 expression appear to lead to neu-
ronal death. Since the mechanisms of degeneration
in prion diseases may be multiple and complex, our
findings contribute to an understanding of the molec-
ular mechanisms associated with the development of
prion pathogenesis and a role for phospho-tau protein
in this process.
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†Deceased.
This work was supported by Fondo Nacional de
Ciencia y Tecnologia, FONDOCyT, from the Min-
istry of Higher Education, Science and Technology,
Dominican Republic (2015-3A2-127 to MP-H) and
(2018-2019-2A3-208 to JL-M and MP-H).
Authors’ disclosures available online (https://
www.j-alz.com/manuscript-disclosures/20-1308r2).
REFERENCES
[1] du Plessis DG (2008) Prion protein disease and neuropathol-
ogy of prion disease. Neuroimaging Clin N Am 18, 163-
182.
[2] Kaneko M, Sugiyama N, Sasayama D, Yamaoka K, Miya-
kawa T, Arima K, Tsuchiya K, Hasegawa K, Washizuka
S, Hanihara T, Amano N, Yagishita S (2008) Prion disease
causes less severe lesions in human hippocampus than other
parts of brain. Psychiatry Clin Neurosci 62, 264-270.
[3] Kim MO, Geschwind MD (2015) Clinical update of Jakob-
Creutzfeldt disease. Curr Opin Neurol 28, 302-310.
[4] Imran M, Mahmood S (2011) An overview of animal prion
diseases. Virol J 8, 493.
[5] Mastrianni JA (2010) The genetics of prion diseases. Genet
Med 12, 187-195.
[6] Castle AR, Gill AC (2017) Physiological functions of the
cellular prion protein. Front Mol Biosci 4, 19.
[7] Hetz C, Maundrell K, Soto C (2003) Is loss of function of
the prion protein the cause of prion disorders? Trends Mol
Med 9, 237-243.
[8] Biasini E, Turnbaugh JA, Unterberger U, Harris DA (2012)
Prion protein at the crossroads of physiology and disease.
Trends Neurosci 35, 92-103.
[9] Prusiner SB (1982) Novel proteinaceous infectious particles
cause scrapie. Science 216, 136-144.
[10] Jeffrey M, Gonzalez L (2007) Classical sheep transmissible
spongiform encephalopathies: Pathogenesis, pathological
phenotypes and clinical disease. Neuropathol Appl Neuro-
biol 33, 373-394.
[11] Gambetti P, Cali I, Notari S, Kong Q, Zou WQ, Surewicz
WK (2011) Molecular biology and pathology of prion
strains in sporadic human prion diseases. Acta Neuropathol
121, 79-90.
[12] Maddox RA, Person MK, Blevins JE, Abrams JY, Appleby
BS, Schonberger LB, Belay ED (2020) Prion disease inci-
dence in the United States: 2003-2015. Neurology 94,
e153-e157.
[13] Arendt T, Stieler JT, Holzer M (2016) Tau and tauopathies.
Brain Res Bull 126, 238-292.
[14] Hansra GK, Popov G, Banaczek PO, Vogiatzis M, Jegathees
T, Goldbury CS, Cullen KM (2019) The neuritic plaque in
Alzheimer’s disease: Perivascular degeneration of neuronal
processes. Neurobiol Aging 82, 88-101.
[15] Martin L, Latypova X, Terro F (2011) Post-translational
modifications of tau protein: Implications for Alzheimer’s
disease. Neurochem Int 58, 458-471.
[16] Chi NF, Lee YC, Lu YC, Wu HM, Soong BW (2010)
Transmissible spongiform encephalopathies with P102L
mutation of PRNP manifesting different phenotypes: Clin-
ical, neuroimaging, and electrophysiological studies in
Chinese kindred in Taiwan. J Neurol 257, 191-197.
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